SBIR/STTR Research Award

Development of Novel Prion Disease Diagnostic

Award identifier cc1aa408fdcbae6d6573d3ac12a8987837af061bff314f6c5984c7d0b0c23629Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$408,225

Program and phase

SBIR · Phase I

Award year

2018

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Amydis Diagnostics Inc.
Proposal award date
2018-09-30
Contract end date
2019-08-31
UEI
LCXNBB1KM9K9
Solicitation number
PA15-354
Topic code
NIA

Research abstract

PROJECT SUMMARY Prion diseases are a class of neurological disorders similar to Alzheimer s disease that are fataltransmissibleand affect both humans and animalsThe most common human prion diseaseCreutzfeldt Jakob diseaseCJDis sometimes called the andquot great mimickerandquotbecause it causes symptoms that occur in many other neurological diseases like Alzheimer s DiseaseSimilar to Alzheimer s diseaseearly and accurate testing of CJD is necessary to distinguish this untreatable disease from treatable rapidly progressive dementiasCommon symptoms of CJDlike Alzheimer s diseaseinclude behavioral and personality changesconfusion and memory problemslack of coordinationand visual disturbancesInterestinglyrecent reports have indicated prion proteins in post mortem retinal tissue of CJD patients similar to reports in the literature in Alzheimer s Disease patientsAmydis is developing an innovative new approach to diagnosing amyloid associated diseases like Alzheimer s disease and CJD by way of an eye examThe proposed research will result in a noninvasive screening test for detecting prions in the eyeas a window to the brainfor early detection of CJD an analogous approach to our initial program in Alzheimer s diseaseIn additionthis test will be utilized by hospitals to reduce the potential transmission of the disease to other patients like patients with Alzheimer s Disease undergoing neurological testsAmydis has designed its technology to use existing ophthalmic instrumentation thereby allowing for an easy transition into commercial practice by physicians Project Narrative Creutzfeldt Jakob DiseaseCJDis characterized by the deposition of insoluble protein aggregates in the brain that are referred to as amyloidsRecentlythese amyloids have been identified in retinal tissue in diseased individualsThe proposed research aims to advance a non invasivediagnostic to image amyloid deposits through the eye

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

11 SBIR/STTR records share this UEI (2015–2025). Reported award amounts total $16,496,188. Reported amounts are not federal obligations.

Phases: Phase II, Phase I, Phase II – Direct to Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.